Answers are grounded in this paper and cite their sources.
The aim of this article is to describe the new actions of botulinum toxin A for chronic pain treatment. BT/A inhibits the exocytosis of synaptic vesicles containing the pain mediators neurotransmitters, reduces the post traumatic trigeminal neuralgia pain, inhibits the release of microglia derived TNF-α as well as other pro inflammatory cytokines, viable treatment option in the case of patients who do not respond to conservative treatment methods of chronic pain (medication) BT/A is an emerging treatment for chronic pain; patients with severe chronic facial pain, not responding to conventional treatments, can respond to botulinum type a injections
No takes yet. Share an insight, caveat, or question.
Hajj et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: